Key Points
- Insider sale: Director William Guyer sold 4,500 shares on Nov. 25 at an average price of $80.90 for $364,050, leaving him with 787 shares (an 85.11% reduction); this follows three prior sales of 20,000 shares each in Sept., Oct. and early Nov., indicating ongoing insider selling.
- Recent results: Corcept missed expectations for the quarter (EPS $0.16 vs. $0.18 consensus; revenue $207.6M vs. $223.8M) though revenue rose 13.8% year‑over‑year; the stock trades near $79.80 with a market cap of about $8.39B and a P/E around 70.6.
- Analyst view: Coverage is mixed (four Buys, two Holds, one Sell) with an average MarketBeat consensus rating of "Hold" and a consensus target price of $135.25.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) insider William Guyer sold 4,500 shares of the business's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $80.90, for a total transaction of $364,050.00. Following the completion of the sale, the insider owned 787 shares in the company, valued at $63,668.30. This represents a 85.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.
William Guyer also recently made the following trade(s):
- On Wednesday, November 5th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $75.36, for a total transaction of $1,507,200.00.
- On Tuesday, October 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $89.94, for a total transaction of $1,798,800.00.
- On Tuesday, September 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The shares were sold at an average price of $70.49, for a total transaction of $1,409,800.00.
Corcept Therapeutics Trading Down 0.6%
CORT opened at $79.80 on Thursday. The stock has a 50-day moving average of $78.26 and a 200 day moving average of $74.03. Corcept Therapeutics Incorporated has a 12 month low of $49.00 and a 12 month high of $117.33. The firm has a market cap of $8.39 billion, a P/E ratio of 70.62 and a beta of 0.43.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.02). The company had revenue of $207.64 million during the quarter, compared to the consensus estimate of $223.78 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. Corcept Therapeutics's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.41 earnings per share. Corcept Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of research analysts have weighed in on CORT shares. Wall Street Zen cut shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, October 18th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $140.00 price target on shares of Corcept Therapeutics in a research note on Thursday, September 25th. Piper Sandler reduced their price objective on shares of Corcept Therapeutics from $131.00 to $121.00 and set an "overweight" rating on the stock in a research report on Friday, August 1st. Wolfe Research initiated coverage on shares of Corcept Therapeutics in a research note on Tuesday, November 18th. They issued a "peer perform" rating for the company. Finally, Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Corcept Therapeutics in a research note on Wednesday, November 19th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Corcept Therapeutics has an average rating of "Hold" and a consensus target price of $135.25.
View Our Latest Analysis on Corcept Therapeutics
Institutional Trading of Corcept Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of CORT. Advisory Services Network LLC purchased a new position in Corcept Therapeutics during the 3rd quarter worth $25,000. Clearstead Advisors LLC increased its stake in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock valued at $26,000 after buying an additional 193 shares during the period. Golden State Wealth Management LLC bought a new stake in shares of Corcept Therapeutics in the 2nd quarter valued at about $28,000. Huntington National Bank raised its stake in Corcept Therapeutics by 54.0% in the second quarter. Huntington National Bank now owns 479 shares of the biotechnology company's stock worth $35,000 after buying an additional 168 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company's stock worth $38,000 after buying an additional 395 shares during the period. Institutional investors own 93.61% of the company's stock.
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
